Investigators performed a literature review to better understand how delays in treatment might affect clinical outcomes in urologic cancer patients, including the risk of upstaging, recurrence, and mortality.
In a study of T2 to T3 RCC patients, lymph node dissection did not significantly improve overall survival.
Among patients who undergo treatment for T1a renal cell carcinoma, 5- and 10-year cancer-specific mortality rates rise with age across treatment modalities, a study found.
Active surveillance for small renal masses in older patients offers long-term oncologic efficacy similar to that of partial or radical nephrectomy.
Separate studies demonstrated that partial nephrectomy could be an acceptable alternative to radical nephrectomy in selected cases of high-risk kidney cancer and large renal masses.
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
Median overall survival (OS) times for the young, intermediate, and elderly groups were 20.0, 17.3, and 21.0 months, respectively.
Patients who underwent image-guided percutaneous cryoablation of cT1 renal cell carcinoma tumors had an estimated local tumor progression-free survival rate 94.9% at 5 years.
In a study of SEER registry patients with renal cell carcinoma, variant histology subtypes were associated with higher cancer-specific mortality than grade 4 clear-cell carcinoma.
Access a treatment regimen chart with detailed information for renal cell carcinoma, including tyrosine kinase inhibitors and cytokine therapy.
